Monali Praharaj

Monali Praharaj

Auto-generated profile, based on publicly available information

Monali Praharaj

Pathobiology Graduate Program, Johns Hopkins University School of Medicine, Baltimore, Maryland. 1

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2024 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
MPMonali Praharaj
Monali Praharaj
FSFan Shen
Fan Shen
ALAlex J. Lee
Alex J. Lee
LZLiang Zhao
Liang Zhao
TNThomas R. Nirschl
Thomas R. Nirschl
JZJelani C. Zarif
Jelani C. Zarif
Glutamine metabolism in tumor microenvironments critically regulates antitumor immunity. Using the glutamine-antagonist prodrug JHU083, we report potent tumor growth inhibition in urologic tumors by JHU083-reprogrammed tumor-associated macrophages (TAMs) and tumor-infiltrating monocytes. We show JHU083-mediated glutamine antagonism in tumor microenvironments induced by TNF, proinflammatory, and mTORC1 signaling in intratumoral TAM clusters. JHU083-reprogrammed TAMs also exhibited increased tumor cell phagocytosis and diminished proangiogenic capacities. In vivo inhibition of TAM glutamine consumption resulted in increased glycolysis, a broken tricarboxylic acid (TCA) cycle, and purine metabolism disruption. Although the antitumor effect of glutamine antagonism on tumor-infiltrating T cells was moderate, JHU083 promoted a stem cell–like phenotype in CD8+ T cells and decreased the abundance of regulatory T cells. Finally, JHU083 caused a global shutdown in glutamine-utilizing metabolic pathways in tumor cells, leading to reduced HIF-1α, c-MYC phosphorylation, and induction of tumor cell apoptosis, all key antitumor features. Altogether, our findings demonstrate that targeting glutamine with JHU083 led to suppressed tumor growth as well as reprogramming of immunosuppressive TAMs within prostate and bladder tumors that promoted antitumor immune responses. JHU083 can offer an effective therapeutic benefit for tumor types that are enriched in immunosuppressive TAMs.


9 July 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
RDRuchi Jain Dey
Ruchi Jain Dey
BDBappaditya Dey
Bappaditya Dey
ASAlok Kumar Singh
Alok Kumar Singh
MPMonali Praharaj
Monali Praharaj
WBWilliam R Bishai
William R Bishai
Stimulator of interferon genes (STING) has emerged as a key signaling receptor that induces proinflammatory cytokines, and small molecule STING agonists are being developed as anticancer and antiviral agents. Here we report a strategy of delivering a STING agonist from within live BCG. We generated a recombinant BCG (BCG- disA -OE) that overexpresses the endogenous mycobacterial diadenylate cyclase gene and releases high levels of the STING agonist c-di-AMP. In macrophages BCG- disA -OE elicited statistically significantly stronger TNF-α, IL-6, IL-1β, IRF3, and IFN-β levels than BCG-WT. In a 24-week guinea pig vaccination- Mtb challenge model, BCG- disA -OE reduced lung weights, pathology scores, and Mtb CFU counts in lungs by 28% (p<0.05), 34%, and 2.0 log10 CFU units (p < 0.5) compared with BCG-WT, respectively. Overproduction of the STING agonist c-di-AMP significantly enhanced the protective efficacy of BCG against pulmonary and extrapulmonary tuberculosis. Our findings support the development of BCG-vectored STING agonists as a TB vaccine strategy.

2 July 2024
Verified
Other
Open access
MPMonali Praharaj
Monali Praharaj
FSFan Shen
Fan Shen
ALAlex J. Lee
Alex J. Lee
LZLiang Zhao
Liang Zhao
TNThomas R. Nirschl
Thomas R. Nirschl
JZJelani C. Zarif
Jelani C. Zarif
JHU083-mediated glutamine antagonism reprograms TME, differentially induces TAMs, TIMs, inflammatory TNF signaling and proliferation in TAMs/TIMs. A, UMAP and stacked bar plots showing the diversity and differential abundance of TAMs and monocyte (TIM) clusters in B6CaP tumors at an early point (day 7 posttreatment) using scRNA-seq (n = 6) across samples. UMAP, uniform manifold approximation and projection for dimension reduction. B, Density plots of different TAM and TIM clusters in control and JHU083-treated B6CaP tumors (identified in A). C, DEG scores were calculated for each TAM cluster based on the GSEA of significant DEGs from bulk RNA-seq of JHU083-treated vs. control TAMs (day 14 posttreatment, late time point; n = 6/group). D, UMAP plot based on the DEG scores identified using bulk RNA-seq of B6CaP-TAMs from C. UMAP, uniform manifold approximation and projection for dimension reduction. E, GSEA between JHU083-treated vs. control cells from the proliferative TAMs and TAM2. F, GSEA between bulk RNA-sequenced JHU083-treated TAMs and control TAMs sorted from B6CaP tumors (day 18 posttreatment; n = 6/group). G, Volcano plot of top DEGs from the TAM2 cluster between JHU083-treated vs. control. H, Volcano plot of top DEGs between JHU083-treated vs. control samples from bulk RNA-seq data. I, Intracellular quantification of the percentage (%) TNF+ population in TAMs and TIMs in B6CaP tumors. J, Intracellular expression of percentage (%) Ki-67+ TAMs in JHU083-treated TAMs vs. control B6CaP tumors, and (K) clusters identified from A overlaid using RNA velocity analysis. The root cells are the undifferentiated cells, and the developmental endpoints are the differentiated cells connected via arrows pointing to the likely developmental paths. Briefly, DEGs were calculated with DESeq2 in the bulk RNA-seq data, and with the Wilcoxon rank-sum test for the scRNA-seq data. The data are presented as mean values ± SEM. Statistical analyses were performed using either t test or a two-way ANOVA using Bonferroni’s multiple comparisons (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).


2 July 2024
Verified
Other
Open access
MPMonali Praharaj
Monali Praharaj
FSFan Shen
Fan Shen
ALAlex J. Lee
Alex J. Lee
LZLiang Zhao
Liang Zhao
TNThomas R. Nirschl
Thomas R. Nirschl
JZJelani C. Zarif
Jelani C. Zarif
JHU083-induced glutamine antagonism promotes phagocytosis of tumor cells by TAMs and decreases angiogenesis in the TME. A, Tumor volume measurement of MB49 tumors in different treatment conditions. JHU083 treatment decreases tumor growth in MB49-RFP+ tumors relative to nontreated (n = 5 or 6/group) tumors. B, Representative flow cytometry plots of RFP+ MB49 tumor cells in TAMs in JHU083-treated vs. vehicle-treated tumors. C, Percentage of RFP+ cells within overall TAMs, CD206+ TAMs (M2-TAMs), and CD86+ MHCII+ TAMs (M1-TAMs) in MB49 tumors in control vs. JHU083-treated tumors. D, Percentage of RM1-RFP+ cells and corresponding mean fluorescence intensity (gMFI) of TAMs (n = 4/group) in control vs. JHU083-treated tumors. E, Schematic diagram showing the determination of the phagocytic activity of TAMs. Briefly, DON-treated, PBMC-derived macrophages were cocultured with CFSE-labeled PC3 cells, and phagocytic activity was determined using flow cytometry. F, Representative photomicrographs showing increased phagocytosis in DON-treated and PKH26-labeled macrophages (PKH26 MAC) cocultured with CFSE-labeled PC3 (CFSE PC3) by immunofluorescence microscopy and quantification using flow cytometry. G, Violin plots of phagocytosis UCell scores on TAM_1, TAM_2, Inflam_TAM, and Prolif_TAM (Wilcoxon rank-sum test) identified in scRNA-seq analysis of CD45+ cells from B6CaP tumors. H, Violin plot for Myo1e expression in all TAMs in B6CaP-derived TAMs identified in scRNA-seq analysis of CD45+ cells from B6CaP tumors. I, IHC-based quantification of CD31+ area intensity in B6CaP tumors (n = 3/group), and (J) IHC quantification of CD31 intensity in MB49 tumors. Statistical analyses were performed using t test or two-way ANOVA using Bonferroni’s multiple comparisons. Violin plots from scRNA-seq studies are analyzed using the Wilcoxon rank-sum test. (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).